Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30525081 | 1.00 | ALDH1A1 (0.58) | ALDH1A1PTGESALOX5CA12CA1 | |
| SCHEMBL30485071 | 0.92 | ALDH1A1 (0.56) | ALDH1A1PTGESALOX5CA12CA1 | |
| SCHEMBL30555025 | 0.90 | ALDH1A1 (0.53) | ALDH1A1PTGESALOX5CA12CA1 | |
| SCHEMBL31376243 | 0.81 | HSP90AA1 (0.51) | ALDH1A1CA12CA1CA7CA9 | |
| SCHEMBL21784054 | 0.77 | PTGES (0.49) | ALDH1A1PTGESALOX5CA12CA1 | |
| Mallotochromene SCHEMBL30616016 | 0.74 | KDM4E (0.59) | ALDH1A1PTGESALOX5HIF1AKDM4E | |
| SCHEMBL21765950 | 0.74 | HIF1A (0.67) | HIF1AHSP90AA1 | |
| SCHEMBL29379773 | 0.72 | ALDH1A1 (0.50) | ALDH1A1PTGESALOX5CA12CA1 | |
| SCHEMBL16244979 | 0.71 | HSP90AA1 (0.50) | PTGESALOX5HIF1AHSP90AA1 | |
| SCHEMBL30040796 | 0.71 | HSP90AA1 (0.50) | PTGESALOX5HIF1AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3847163-B1 | BIOACTIVE COMPOUND | HARDIE HEALTH LTD (NZ) | 2023-07-19 | — | — | EP | disclosed |
| US-20210332023-A1 | BIOACTIVE COMPOUND | HARDIE HEALTH LIMITED (NZ) | 2021-10-28 | — | — | US | disclosed |
| WO-2020044245-A1 | BIOACTIVE COMPOUND | HARDIE HEALTH LIMITED (NZ) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332023-A1 | BIOACTIVE COMPOUND | MLX, MELK, BMX | ALDH1A1 2370/4885PTGES 351/4885ALOX5 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.